Joseph J Palamar1, Austin Le2. 1. Department of Population Health, New York University Langone Medical Center, New York, NY, United States. Electronic address: joseph.palamar@nyumc.org. 2. New York University College of Dentistry, New York, NY, United States.
Abstract
BACKGROUND: Amphetamine is the most prevalent prescription stimulant in the United States, both medically and nonmedically. Reliable data on nonmedical use is needed to continue to inform prevention. To determine whether adolescents accurately self-report nonmedical amphetamine use, we compared self-reports of nonmedical amphetamine use and nonmedical Adderall use in a national sample. METHODS: We examined self-reported nonmedical Adderall and amphetamine use in a nationally representative sample of 24,740 high school seniors in the Monitoring the Future study (2010-2015). We examined prevalence and correlates of discordant responses among past-year Adderall users, defined as reporting past-year nonmedical Adderall use, but not reporting past-year nonmedical amphetamine use. RESULTS: While 6.9% reported nonmedical Adderall use and 7.9% reported nonmedical amphetamine use, over a quarter (28.7%) of Adderall users reported no amphetamine use. Those at highest risk for Adderall use tended to be at lower odds of providing a discordant response. Older students (aged ≥18), black students, and those with parents of lower educational attainment were more likely to report no amphetamine use, despite reporting Adderall use. Lifetime use of various drugs was associated with decreased odds of providing a discordant response; however, only nonmedical opioid use was associated with significant decreased odds in multivariable models. Disapproval towards amphetamine use increased odds of providing a discordant response, while higher exposure to users decreased odds of providing a discordant response. CONCLUSION: Prevalence of nonmedical amphetamine use may be underreported on some surveys, particularly among specific subpopulations. Future surveys must ensure accurate and consistent responses.
BACKGROUND:Amphetamine is the most prevalent prescription stimulant in the United States, both medically and nonmedically. Reliable data on nonmedical use is needed to continue to inform prevention. To determine whether adolescents accurately self-report nonmedical amphetamine use, we compared self-reports of nonmedical amphetamine use and nonmedical Adderall use in a national sample. METHODS: We examined self-reported nonmedical Adderall and amphetamine use in a nationally representative sample of 24,740 high school seniors in the Monitoring the Future study (2010-2015). We examined prevalence and correlates of discordant responses among past-year Adderall users, defined as reporting past-year nonmedical Adderall use, but not reporting past-year nonmedical amphetamine use. RESULTS: While 6.9% reported nonmedical Adderall use and 7.9% reported nonmedical amphetamine use, over a quarter (28.7%) of Adderall users reported no amphetamine use. Those at highest risk for Adderall use tended to be at lower odds of providing a discordant response. Older students (aged ≥18), black students, and those with parents of lower educational attainment were more likely to report no amphetamine use, despite reporting Adderall use. Lifetime use of various drugs was associated with decreased odds of providing a discordant response; however, only nonmedical opioid use was associated with significant decreased odds in multivariable models. Disapproval towards amphetamine use increased odds of providing a discordant response, while higher exposure to users decreased odds of providing a discordant response. CONCLUSION: Prevalence of nonmedical amphetamine use may be underreported on some surveys, particularly among specific subpopulations. Future surveys must ensure accurate and consistent responses.
Authors: Theresa A Cassidy; Sajan Varughese; Leo Russo; Simon H Budman; Thomas A Eaton; Stephen F Butler Journal: J Atten Disord Date: 2012-12-26 Impact factor: 3.256
Authors: Joseph J Palamar; Alberto Salomone; Enrico Gerace; Daniele Di Corcia; Marco Vincenti; Charles M Cleland Journal: Int J Drug Policy Date: 2017-08-12
Authors: Joseph J Palamar; Patricia Acosta; Fermín Fernández Calderón; Scott Sherman; Charles M Cleland Journal: Am J Drug Alcohol Abuse Date: 2017-05-09 Impact factor: 3.829
Authors: Lian-Yu Chen; Rosa M Crum; Eric C Strain; G Caleb Alexander; Christopher Kaufmann; Ramin Mojtabai Journal: J Clin Psychiatry Date: 2016-03 Impact factor: 4.384
Authors: Natalie S Levy; Joseph J Palamar; Stephen J Mooney; Charles M Cleland; Katherine M Keyes Journal: Ann Epidemiol Date: 2022-01-03 Impact factor: 6.996
Authors: Ahmed K Emara; Daniel Grits; Alison K Klika; Robert M Molloy; Viktor E Krebs; Wael K Barsoum; Carlos Higuera-Rueda; Nicolas S Piuzzi Journal: Clin Orthop Relat Res Date: 2021-09-01 Impact factor: 4.755